US Patent Issued to JIANGSU ALPHAMAB BIOPHARMACEUTICALS on Aug. 4 for "Combination of bispecific fusion protein and anti-Her2 antibody for tumor treatment" (Chinese Inventors)

ALEXANDRIA, Va., Aug. 5 -- United States Patent no. 12,698,343, issued on Aug. 4, was assigned to JIANGSU ALPHAMAB BIOPHARMACEUTICALS Co. LTD. (Suzhou, China).

"Combination of bispecific fusion protein and anti-Her2 antibody for tumor treatment" was invented by Ting Xu (Suzhou, China), Kangping Guo (Suzhou, China), Junfang Xu (Suzhou, China), Pilin Wang (Suzhou, China) and Yuhao Jin (Suzhou, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides a use of an immune checkpoint inhibitor in combination with a Her2 inhibitor in the preparation of a medicament for treating tumor in a subject in need thereof, and also provides a pharmaceutical composition comprising an effective amoun...